Latest News for: wee1

Edit

Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response ...

Nasdaq Globe Newswire 18 Feb 2026
... 1 ACESOT-1051 trial evaluating its investigational WEE1 kinase inhibitor APR-1051.
Edit

Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor,

Hastings Tribune 18 Feb 2026
... of targeting WEE1 for this patient populationEmerging .
Edit

Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial (Form 8-K) (Aprea Therapeutics Inc)

Public Technologies 18 Feb 2026
- Represents second patient with PR to harbor PPP2R1A mutation, supporting mechanistic thesis of targeting WEE1 for this patient population ... WEE1 inhibition with an improved therapeutic index.
Edit

Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor ...

Nasdaq Globe Newswire 29 Jan 2026
... study (A Multi-Center Evaluation of WEE1 Inhibitor APR-1051 in Patients with Advanced Solid Tumors).
  • 1

Article Search

tools
×
×
×
×